Mouwasat Medical Services Valuation
Is 4002 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of 4002 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4002?
Key metric:
| What is 4002's PE Ratio? | |
|---|---|
| PE Ratio | 27.4x |
| Earnings | ر.س658.09m |
| Market Cap | ر.س18.42b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.6x |
| Enterprise Value/EBITDA | 19.6x |
| PEG Ratio | 2.1x |
Price to Earnings Ratio vs Peers
How does 4002's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 37x | ||
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 54.2x | 20.5% | ر.س15.7b |
4004 Dallah Healthcare | 32.6x | 14.2% | ر.س15.5b |
4009 Middle East Healthcare | 35.7x | 18.7% | ر.س7.5b |
4005 National Medical Care | 25.6x | 11.1% | ر.س7.1b |
4002 Mouwasat Medical Services | 27.4x | 13.0% | ر.س18.4b |
Price to Earnings Ratio vs Industry
How does 4002's PE Ratio compare vs other companies in the SA Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price to Earnings Ratio vs Fair Ratio
What is 4002's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 27.4x |
| Fair PE Ratio | 33.7x |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 15:31 |
| End of Day Share Price | 2025/02/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mouwasat Medical Services Company is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jassim Al-Jubran | Aljazira Capital Company |
| Rim Ben Salah Gharbi | AlphaMena |
| Kais Kriaa | AlphaMena |